Dr. Maude is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3401 Civic Center Blvd
Children's Hospital Of Philadelphia - Hem/Onc
Philadelphia, PA 19104Phone+1 215-590-3535Fax+1 215-590-3992
Education & Training
- Children's Hospital of PhiladelphiaFellowship, Pediatric Hematology/Oncology, 2009 - 2012
- Children's Hospital of PhiladelphiaResidency, Pediatrics, 2006 - 2009
- Perelman School of Medicine at the University of PennsylvaniaClass of 2006
Certifications & Licensure
- PA State Medical License 2006 - 2024
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL Start of enrollment: 2019 Jan 18
Publications & Presentations
PubMed
- Therapies and outcomes following extramedullary relapse of pediatric and young adult ALL after CD19 CAR T-cell therapy.Barbara D Friedes, Amanda M DiNofia, Emma Iannone, Yimei Li, Susan R Rheingold
Blood Advances. 2025-01-28 - Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies.Julie K Jadlowsky, Elizabeth O Hexner, Amy Marshall, Stephan A Grupp, Noelle V Frey
Nature Medicine. 2025-01-20 - Inconsistent Reporting and Definitions of Time-to-Event Endpoints in CAR T Clinical Trials: A Review.Connor B Grady, Yimei Li, Shannon L Maude, Elizabeth O Hexner, Noelle V Frey
Transplantation and Cellular Therapy. 2024-11-26
Journal Articles
- Induction of Resistance to Chimeric Antigen Receptor T Cell Therapy by Transduction of a Single Leukemic B CellVijay G Bhoj, David M Barrett, Carl H June, Stephan A Grupp, David E Ambrose, Saar I Gill, Marco Ruella, Bruce L Levine, Shannon L Maude, Nature
Abstracts/Posters
- Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell EfficacyShannon L. Maude, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Cytogenetic Characteristics and Outcomes of Patients Receiving CTL019 CAR T Cell TherapyShannon L. Maude, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Trends in Inpatient and Intensive Care Resource Utilization after Chimeric Antigen Receptor T Cell Therapy for Pediatric Acute Lymphoblastic Leukemia from 2012-2019Shannon L. Maude, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Lectures
- CD19-Directed CAR T-Cell (CTL019) Product Viability and Clinical Outcomes in Non-Hodgkin Lymphomas and B-Cell Acute Lymphoblastic Leukemia2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- High Vs. Low-Intensity Bridging Chemotherapy in Children with Acute Lymphoblastic Leukemia Awaiting Chimeric Antigen Receptor T-Cell Therapy: A Population-Based Study ...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Integrating CAR T-Cell Therapy Into the Treatment of Lymphoma, Myeloma, and Leukemia: Strategies for Maximizing Patient Outcomes60th American Society of Hematology Annual Meeting - 11/30/2018
Press Mentions
- Wugen to Present Clinical Data at the 2024 ASH Annual Meeting Ahead of Pivotal Trial Launch of Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy WU-CART-007December 5th, 2024
- Researchers Use ‘Humanized’ CAR T Cells to Improve Treatment Durability for Patients with ALLSeptember 8th, 2021
- Durable Responses with CAR T-cell Retreatment in Young ALL PatientsJune 25th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: